Effects of full-fat and low-fat dairy on weight control and metabolic health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research aims to clarify how different types of dairy products, specifically full-fat and low-fat, affect health and weight management in both adults and children. The study will involve families with at least one parent who is obese, and will implement a web-based nutrition intervention to promote increased dairy consumption over an 8-week period. Participants will be randomly assigned to one of three groups: one promoting low-fat dairy, one promoting full-fat dairy, and a control group with no intervention. The study will assess various health metrics, including body weight, diet quality, and metabolic health, before, immediately after, and three months post-intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Parent criteria are as follows:

* men and women between 18-55 years
* body mass index (BMI) between 30-40 kg/m2
* absence of pregnancy, breastfeeding or menopause (no menstruation)
* stable body weight (weight change \<5 kg for three months prior to screening).

Family criteria are as follows:

* being a family composed of at least one parent (mother/father) and at least two children between 8 to 16 years old (families between 3 to 5 persons). Families with at least one obese parent (BMI between 30-40 kg/m2) will be recruited since children coming from these families are more at risk of developing obesity and may benefit more from dairy products
* all participants should have no allergies to dairy products or lactose intolerance and be in good general health.
* since we are recruiting adults with obesity and dairy products may positively impact several metabolic markers, those with hypertension or deteriorated blood glucose and lipid profiles and/or taking medications will also be considered.

Where it's running

• Laval University
  Quebec City, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Vicky Drapeau, PhD, RD — Laval University
• Study coordinator: Lucie Brunelle, MSc, RD
• Email: lucie.brunelle@kin.ulaval.ca
• Phone: 4186562131

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.